Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
27.22
+0.09 (0.33%)
At close: Oct 24, 2025, 4:00 PM EDT
27.25
+0.03 (0.11%)
After-hours: Oct 24, 2025, 5:23 PM EDT
Oruka Therapeutics Employees
Oruka Therapeutics had 28 employees as of December 31, 2024.
Employees
28
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,765,516
Market Cap
1.32B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ORKA News
- 5 weeks ago - Oruka Therapeutics Announces $180 Million Private Placement - GlobeNewsWire
- 5 weeks ago - Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 - GlobeNewsWire
- 2 months ago - Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September - GlobeNewsWire
- 4 months ago - Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer - GlobeNewsWire
- 5 months ago - Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody - GlobeNewsWire
- 5 months ago - Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire